The Direxion Daily S&P Biotech Bull 3X Shares (LABU) is an exchange-traded fund designed to provide leveraged exposure to the U.S. biotechnology sector. The ETF is managed by Direxion and trades under the ticker LABU on the NYSE Arca.

Classified as a leveraged equity ETF, the fund seeks to deliver, before fees and expenses, approximately three times the daily performance of the S&P Biotechnology Select Industry Index.

The ETF follows a passive strategy using extensive financial derivatives, including swaps, futures contracts, and other instruments intended to amplify daily exposure to its benchmark index. Because it is a leveraged ETF, the fund’s performance objective is based on daily returns rather than long-term returns.

Composition / Exposure profile

LABU provides exposure primarily associated with:

• Biotechnology.
• Drug development.
• Genetic therapies.
• Immunotherapy.
• Pharmaceutical research.
• U.S. small-cap and mid-cap companies.
• Healthcare innovation.
• Leveraged equity strategies.

The ETF’s performance is particularly sensitive to biotechnology-sector volatility, U.S. equity-market conditions, and healthcare-related regulatory decisions.

Changes in interest rates, clinical-trial outcomes, FDA approvals, and availability of medical research financing may directly affect the fund’s behavior. The ETF may also reflect developments associated with artificial intelligence applications in drug discovery, genetic innovation, and advances in medical therapies.

Because the ETF uses daily leverage, it is subject to compounding effects. Over longer holding periods, especially during volatile market conditions, the ETF’s cumulative performance may diverge significantly from three times the cumulative return of its benchmark index.

Structure and costs

LABU shares trade on the secondary market on the NYSE Arca during regular trading hours. Share creation and redemption occur through authorized participants, a mechanism intended to help align the ETF’s market price with its net asset value (NAV).

The fund charges a management fee as outlined in its prospectus and does not apply a performance fee. LABU may distribute income derived from dividends paid by portfolio companies, although the product’s primary objective is associated with tactical leveraged exposure to the biotechnology sector.

Because the ETF uses derivatives and daily leverage, its behavior may exhibit extremely elevated volatility and heightened sensitivity to short-term market movements.

History and evolution of the ETF

The Direxion Daily S&P Biotech Bull 3X Shares was launched in 2015 during a period marked by growth in sector-focused leveraged ETFs tied to the U.S. biotechnology industry.

Since inception, the fund has reflected movements associated with American biotechnology companies, including sector financing cycles, regulatory developments, and fluctuations in the pharmaceutical innovation environment.

In recent years, LABU has reflected periods of elevated volatility across biotechnology companies, changes in interest rates, developments related to artificial intelligence in healthcare, and shifts in risk appetite within the U.S. equity market.

Additional Information

Direxion Daily S&P Biotech Bull 3X Shares (United States) is an exchange-traded fund (ETF), with assets under management totaling $608.20 million.

Over the past 12 months, Direxion Daily S&P Biotech Bull 3X Shares recorded a return of 80.61%, with its price trading between $117.62 and $341.55 during the same period.

The ETF is traded under the ticker LABU.